Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment.

Vince B C BiemansC Janneke van der WoudeGerard DijkstraAndrea E van der Meulen-de JongMark LöwenbergNanne K de BoerBas OldenburgNidhi SrivastavaJeroen M JansenAlexander G L BodelierRachel L WestAnnemarie C de VriesJeoffrey J L HaansDirk de JongFrank HoentjenMarieke J Pieriknull null

Published in: Alimentary pharmacology & therapeutics (2020)

Ustekinumab was associated with superior effectiveness outcomes when compared to vedolizumab, while safety outcomes were comparable after 52 weeks of treatment in CD patients who have failed anti-TNF treatment.

Keyphrases

randomized controlled trial
rheumatoid arthritis
end stage renal disease
chronic kidney disease
type diabetes
ejection fraction
newly diagnosed
combination therapy
prognostic factors
preterm birth
patients with inflammatory bowel disease
glycemic control